CJC-1295 + Ipamorelin is a growth hormone-releasing peptide stack. CJC-1295 is a GHRH analogue that primes the pituitary for GH release; Ipamorelin is a selective GHRP that triggers the GH pulse — in animal studies, without the cortisol and prolactin elevation seen with older GHRPs. Together, the two are studied for producing a larger GH pulse than either peptide alone.

Quick Answer

For a 5mg CJC-1295 vial and a 5mg Ipamorelin vial: add 2ml BAC water to each → both at 2500 mcg/ml. Commonly referenced research amounts: 300mcg CJC-1295 (12 units) + 200mcg Ipamorelin (8 units) per injection.

Dose Reference Table

Pre-calculated for a 5mg vial + 2ml BAC water = 2,500 mcg/ml concentration. Using a 100-unit (1ml) insulin syringe.

Dose Inject Volume (ml) Syringe Units
100mcg 0.040 ml 4 units
200mcg 0.080 ml 8 units
300mcg 0.120 ml 12 units
500mcg 0.200 ml 20 units
1000mcg 0.400 ml 40 units

About CJC-1295 + Ipamorelin

CJC-1295 + Ipamorelin is one of the most popular peptide combinations in growth hormone research. CJC-1295 is a GHRH (growth hormone-releasing hormone) analogue that stimulates the pituitary gland to release GH, while Ipamorelin is a selective GHRP (growth hormone-releasing peptide) that amplifies GH release through a complementary mechanism.

When combined, these two peptides act synergistically — CJC-1295 provides the GHRH signal while Ipamorelin amplifies the response, resulting in a greater GH pulse than either peptide alone. This combination is popular in research for studying GH secretion, body composition, recovery, and sleep quality.

The blend is commonly available as a pre-mixed vial (most often in a 1:1 ratio by mass) or as two separate vials administered together. For a 5mg blend vial with 2ml BAC water, concentration is 2500 mcg/ml. A typical dose of 300mcg CJC-1295 + 200mcg Ipamorelin in a blend would require calculating based on the actual blend ratio.

In research settings, this combination is typically studied 1–3 times daily, with the final dose timed before sleep to align with the body's natural nighttime GH pulsatility.

How this calculator works

Every result comes from the same three formulas used for any lyophilized peptide: concentration (mcg/ml) = vial mg × 1,000 ÷ BAC water ml; injection volume (ml) = desired dose mcg ÷ concentration; syringe units = injection volume ml × 100 on a U-100 syringe.

For the preset CJC-1295 + Ipamorelin setup on this page: a 5mg vial mixed with 2ml of bacteriostatic water gives a concentration of 2,500 mcg/ml. A 300mcg dose then needs 0.12ml, which is 12 units on a 100-unit insulin syringe.

The full methodology, with worked examples and the assumptions behind each formula, is on the methodology page.

Accuracy & limitations

The arithmetic itself is exact — the same inputs always produce the same output. Real-world accuracy depends on things outside the calculator: actual vial contents can vary slightly from the labeled amount within manufacturing tolerance, the BAC water volume should be measured carefully, and syringe readings are taken at the bottom edge of the plunger. Reconstituted peptides also degrade over time (the common guidance is to use within about 28 days refrigerated), which the math does not model. This tool does arithmetic only — it does not recommend doses, and it is not medical advice.

Last reviewed: September 2026 · Content, formulas and sources checked by Kanika

Frequently Asked Questions

Common research doses are 100–300mcg of each peptide per injection, 1–3 times daily. The final dose of the day is often timed before sleep to align with natural GH pulsatility.
CJC-1295 with DAC (Drug Affinity Complex) binds to albumin, extending its half-life to 6–8 days, allowing weekly dosing. CJC-1295 without DAC (also called Mod GRF 1-29) has a shorter half-life of 30 minutes, requiring more frequent dosing.
Research suggests GH release is blunted by elevated blood glucose. For this reason, researchers often administer these peptides in a fasted state (2+ hours after eating) in study designs aiming to maximize GH release.
Research protocols typically span 3–6 months, with some researchers cycling on and off. Body composition and recovery endpoints are typically assessed over weeks to months of use.
Yes — when using separate vials, CJC-1295 and Ipamorelin can be drawn into the same syringe for a single injection. This is a common practice in research protocols. Blend vials pre-combine both peptides.